Tyra Biosciences Inc (TYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.62 Million) by net assets ($259.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tyra Biosciences Inc (TYRA) total market value for the company's overall valuation and market capitalisation.
Tyra Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tyra Biosciences Inc (TYRA) share price today for real-time trading data and today's change.
Tyra Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tyra Biosciences Inc ranked by their cash flow conversion efficiency. Review TYRA financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Electric Group Company Limited
F:USR
|
0.061x |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
0.029x |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
0.042x |
|
Sigma Lithium Resources Corp
V:SGML
|
0.216x |
|
Metropolitan Bank Holding
NYSE:MCB
|
0.046x |
|
Hengbao Co Ltd
SHE:002104
|
0.011x |
|
Ranhill Holdings Ltd
KLSE:5272
|
0.153x |
|
Zhejiang Songyuan Automotive Safety
SHE:300893
|
0.019x |
Annual Cash Flow Conversion Efficiency for Tyra Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tyra Biosciences Inc from 2019 to 2025. Also see how large is Tyra Biosciences Inc's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $259.18 Million | $-95.14 Million | -0.367x | -80.54% |
| 2024-12-31 | $343.15 Million | $-69.77 Million | -0.203x | +17.16% |
| 2023-12-31 | $204.26 Million | $-50.14 Million | -0.245x | -25.86% |
| 2022-12-31 | $257.83 Million | $-50.28 Million | -0.195x | -147.84% |
| 2021-12-31 | $301.74 Million | $-23.75 Million | -0.079x | -113.82% |
| 2020-12-31 | $-13.64 Million | $-7.76 Million | 0.569x | +3.08% |
| 2019-12-31 | $-4.74 Million | $-2.62 Million | 0.552x | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more